PIK3CG and metastatic prostate carcinoma: OncoPrints displaying the percentage frequency of each type of genetic aberration assessed within each dataset (i.e., gene mutation, amplification and deep deletion) highlight that PI3K-AKT-mTOR pathway genetic alterations are commonplace in primary and metastatic prostate cancer, and illustrate that the wide range of genetic events observed have a tendency to co-occur (Figures S1–S3 and Tables S1–S3, summarized in Table 1).